A case of thyrotoxicosis after sunitinib treatment.
- Author:
Ho Young LEE
1
;
Mi Kyung KIM
;
Nam Keong KIM
;
Hye Soon KIM
;
Seong Yeol RYU
;
Ki Young KWON
;
Keun Gyu PARK
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. kgpark@dsmc.or.kr
- Publication Type:Case Report
- Keywords:
Sunitinib;
Thyrotoxicosis
- MeSH:
Carcinoma, Renal Cell;
Humans;
Hypothyroidism;
Indoles;
Pyrroles;
Thyrotoxicosis
- From:Korean Journal of Medicine
2010;78(4):503-506
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sunitinib is a tyrosine-kinase inhibitor used to treat metastatic renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors. Hypothyroidism is a common side effect of sunitinib therapy. Nevertheless, overt thyrotoxicosis induced by destructive thyroiditis after sunitinib treatment is very rare. Here, we report a patient with overt thyrotoxicosis related to sunitinib therapy.
